An undergraduate class in abnormal psychology and a lifelong interest in technology helped to set Michael Hufford on a career path that now includes the co-founding of five companies. As CEO of Harm Reduction Therapeutics, a nonprofit pharmaceutical company, Hufford hopes to make a cheap, OTC version of naloxone widely available to help prevent unnecessary deaths from opioid overdoses.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Entrepreneur Carlo Rivis, one of In Vivo’s Rising Leaders, brought his disruptive innovation approaches to in-silico trials and digital avatar developer Computational Life, and now he is doing the same at Innovation Discovery.

Theragnostics’ CEO Greg Mullen aims to use his wide-ranging “hands-on” scientific and commercial experience to help clinch a $45m series A financing round that will fund a Phase I/II basket study to develop the biotech’s lead radiotherapeutic PARP inhibitor.

Co-founded by Sebastian Nijman and Thijn Brummelkamp in 2017, Scenic Biotech is a spinout of the Netherlands Cancer Institute and Oxford University. It was established with a focus on identifying genetic modifiers, or genes that suppress or block the disease-causing effects of a mutated gene in the body. In Vivo spoke with incoming CEO Oscar Izeboud about the company’s next steps, and the potential for genetic modifiers to address unmet needs in the rare disease space, and beyond.

Royal Philips would not routinely invest 10% of its sales in R&D without working with providers to discover their precise needs, says CEO Frans van Houten.